Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study-Reference-Cited by-同舟云学术

Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study

Published:2016 Issue:6 Volume:27 Page:665-677
ISSN:0915-7441
Container-title:Japanese Journal of Thrombosis and Hemostasis
language:en
Short-container-title:Nihon Kessen Shiketsu Gakkaishi

Author:

HANABUSA Hideji¹,SHIMA Midori²,NOGAMI Keiji²,MATSUSHITA Tadashi³,FUKUTAKE Katsuyuki⁴,TAKI Masashi⁵,SAKAI Michio⁶,DONG Yingwen⁷,NEELAKANTAN Srividya⁷,CRISTIANO Lynda M.⁷,PIERCE Glenn F.⁷,MEI Baisong⁷

Affiliation:

1. Department of Hematology, Ogikubo Hospital

2. Nara Medical University

3. Department of Transfusion, Nagoya University Hospital

4. Department of Laboratory Medicine, Tokyo Medical University Hospital

5. St. Marianna University School of Medicine Hospital

6. University of Occupational and Environmental Health Hospital

7. Biogen

Publisher

Japanese Society on Thrombosis and Hemostasis

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jjsth/27/6/27_2016_JJSTH_27_6_p665-677/_pdf

Reference35 articles.

1. 1) Mannucci PM, Tuddenham EG: The hemophilias—from royal genes to gene therapy. N Engl J Med 344: 1773–1779, 2001.

2. 2) Luck JV, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS: Hemophilic arthropathy. J Am Acad Orthop Surg 12: 234–245, 2004.

3. 3) Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544, 2007.

4. 4) National Hemophilia Foundation: MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC Document #179. http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf (Accessed 2015.Sept.21).

5. 5) Hacker MR, Geraghty S, Manco-Johnson M: Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 7: 392–396, 2001.